Circulation August 25, 2026 Issue

Hey, Gabriel, your criteria that you're outlining for clinical trial manuscript assessment is very helpful.

You didn't comment specifically on whether you have a preference towards phase two, phase three.

How are you reconciling the stage of development in the program when you're thinking about a paper that comes to you at Circulation?

Well, I think we are interested in all of science as long as it's good and it advances the field.

So in both in phase two and phase three you have groundbreaking stuff and you have me too studies.

So we're less interested in the me too studies.

We're more interested in a phase two trial that will outline or test a new mechanism, a new hypothesis, a new agent.

Um, not in the, uh, wealth as GLT2 inhibitor study.

Great.

Well, that's all very exciting and super informative, Gabriel.

We're really pleased and thrilled to have you as one of our co-leaders for the clinical trial aim at Circulation.

I don't think there's any question that we're off to a very robust start.

We'll be looking forward to advancing a number of studies that are simultaneous publications at the upcoming ESC meeting, and I can't wait to continue to work further with you and the rest of the group to make sure that Circulation is as strong as it can be in the clinical trial space.

Obviously very important for practice-changing updates and guidance for our clinical community.

Hey, Gabriel, your criteria that you're outlining for clinical trial manuscript assessment is very helpful.

You didn't comment specifically on whether you have a preference towards phase two, phase three.

How are you reconciling the stage of development in the program when you're thinking about a paper that comes to you at Circulation?

Well, I think we are interested in all of science as long as it's good and it advances the field.

So in both in phase two and phase three you have groundbreaking stuff and you have me too studies.

So we're less interested in the me too studies.

We're more interested in a phase two trial that will outline or test a new mechanism, a new hypothesis, a new agent.

Um, not in the, uh, wealth as GLT2 inhibitor study.

Great.

Well, that's all very exciting and super informative, Gabriel.

We're really pleased and thrilled to have you as one of our co-leaders for the clinical trial aim at Circulation.

I don't think there's any question that we're off to a very robust start.

We'll be looking forward to advancing a number of studies that are simultaneous publications at the upcoming ESC meeting, and I can't wait to continue to work further with you and the rest of the group to make sure that Circulation is as strong as it can be in the clinical trial space.

Obviously very important for practice-changing updates and guidance for our clinical community.